388 related articles for article (PubMed ID: 18561877)
1. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia.
Miner PB; Rodriguez-Stanley S; Proskin HM; Kianifard F; Bottoli I
Curr Med Res Opin; 2008 Aug; 24(8):2159-72. PubMed ID: 18561877
[TBL] [Abstract][Full Text] [Related]
2. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
Rodriguez-Stanley S; Zubaidi S; Proskin HM; Kralstein JR; Shetzline MA; Miner PB
Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials.
Vakil N; Laine L; Talley NJ; Zakko SF; Tack J; Chey WD; Kralstein J; Earnest DL; Ligozio G; Cohard-Radice M
Am J Gastroenterol; 2008 Aug; 103(8):1906-19. PubMed ID: 18616658
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.
Thumshirn M; Fruehauf H; Stutz B; Tougas G; Salter J; Fried M
Aliment Pharmacol Ther; 2007 Nov; 26(10):1399-407. PubMed ID: 17892526
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia.
Tack J; Van Den Elzen B; Tytgat G; Wajs E; Van Nueten L; De Ridder F; Boeckxstaens G
Neurogastroenterol Motil; 2009 Jun; 21(6):619-26, e23-4. PubMed ID: 19220756
[TBL] [Abstract][Full Text] [Related]
7. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
10. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect.
Majewski M; Jaworski T; Sarosiek I; Sostarich S; Roeser K; Edlavitch SA; Kralstein J; Wallner G; McCallum RW; Sarosiek J
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):430-8. PubMed ID: 17445751
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia.
Tack J; Janssen P; Masaoka T; Farré R; Van Oudenhove L
Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1239-45. PubMed ID: 22813445
[TBL] [Abstract][Full Text] [Related]
12. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
[TBL] [Abstract][Full Text] [Related]
14. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.
Talley NJ; Tack J; Ptak T; Gupta R; Giguère M
Gut; 2008 Jun; 57(6):740-6. PubMed ID: 17965059
[TBL] [Abstract][Full Text] [Related]
15. Review article: tegaserod for chronic constipation.
Johanson JF
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
[TBL] [Abstract][Full Text] [Related]
16. Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia.
Kindt S; Dubois D; Van Oudenhove L; Caenepeel P; Arts J; Bisschops R; Tack J
Neurogastroenterol Motil; 2009 Nov; 21(11):1183-e105. PubMed ID: 19663903
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod use in children: a single-center experience.
Liem O; Mousa HM; Benninga MA; Di Lorenzo C
J Pediatr Gastroenterol Nutr; 2008 Jan; 46(1):54-8. PubMed ID: 18162834
[TBL] [Abstract][Full Text] [Related]
18. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tegaserod in chronic constipation in men.
Fried M; Johanson JF; Gwee KA; Wagner A; Pecher E; Rueegg P
Am J Gastroenterol; 2007 Feb; 102(2):362-70. PubMed ID: 17156137
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
